These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21459960)

  • 21. Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?
    Ramos-Casals M
    Nat Rev Rheumatol; 2010 Nov; 6(11):618-20. PubMed ID: 21037559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction or cessation of antiviral agents in hepatitis B virus carriers treated with biologic agents.
    Ghang B; Lee D; Hwang I; Lee CK; Yoo B; Kim YG
    Clin Exp Rheumatol; 2018; 36(1):170. PubMed ID: 29352838
    [No Abstract]   [Full Text] [Related]  

  • 23. Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus.
    Huang YW; Hu CY; Chen CL; Liao YT; Liu CJ; Lai MY; Chen PJ; Yang SS; Hu JT; Chen DS; Kao JH
    J Med Virol; 2009 Apr; 81(4):588-93. PubMed ID: 19235869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor necrosis factor-alpha blocker induced tuberculosis.
    Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
    J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
    [No Abstract]   [Full Text] [Related]  

  • 25. Infectious complications of biological therapy.
    Haroon N; Inman RD
    Curr Opin Rheumatol; 2009 Jul; 21(4):397-403. PubMed ID: 19412102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
    Takai S; Tsurumi H; Ando K; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Takahashi T; Oyama M; Onishi H; Tomita E; Takami T; Imawari M; Moriwaki H
    Eur J Haematol; 2005 Feb; 74(2):158-65. PubMed ID: 15654908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
    Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies in rheumatic diseases.
    Yuvienco C; Schwartz S
    Med Health R I; 2011 Nov; 94(11):320-4. PubMed ID: 22204094
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours.
    Alexopoulos CG; Vaslamatzis M; Hatzidimitriou G
    Br J Cancer; 1999 Sep; 81(1):69-74. PubMed ID: 10487614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.
    Brunetto MR; Oliveri F; Colombatto P; Moriconi F; Ciccorossi P; Coco B; Romagnoli V; Cherubini B; Moscato G; Maina AM; Cavallone D; Bonino F
    Gastroenterology; 2010 Aug; 139(2):483-90. PubMed ID: 20451520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vital hepatitis reactivation with anti-tumor necrosis factor-alpha: what do we know?
    Zuckerman E
    Isr Med Assoc J; 2013 Jun; 15(6):298-300. PubMed ID: 23882896
    [No Abstract]   [Full Text] [Related]  

  • 34. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers.
    Datta S; Banerjee A; Chandra PK; Chowdhury A; Chakravarty R
    J Med Virol; 2006 Jan; 78(1):53-9. PubMed ID: 16299727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.
    Cheng AL; Hsiung CA; Su IJ; Chen PJ; Chang MC; Tsao CJ; Kao WY; Uen WC; Hsu CH; Tien HF; Chao TY; Chen LT; Whang-Peng J;
    Hepatology; 2003 Jun; 37(6):1320-8. PubMed ID: 12774010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases.
    Fernández-Nebro A; Olivé A; Castro MC; Varela AH; Riera E; Irigoyen MV; García de Yébenes MJ; García-Vicuña R
    Am J Med; 2010 May; 123(5):454-61. PubMed ID: 20399323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus.
    Chu CM; Liaw YF
    Am J Gastroenterol; 2009 Jul; 104(7):1693-9. PubMed ID: 19455130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.